PharmaCyte Biotech, Inc.
PMCB
$0.72
-$0.03-3.73%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 140.47% | 22.35% | -35.79% | -14.64% | -51.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 120.57% | 24.32% | -33.15% | -10.66% | -48.62% |
| Operating Income | -120.57% | -24.32% | 33.15% | 10.66% | 48.62% |
| Income Before Tax | 124.53% | -404.76% | -135.69% | 772.47% | -391.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 124.53% | -404.76% | -135.69% | 772.47% | -391.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 124.53% | -404.76% | -135.69% | 772.47% | -391.57% |
| EBIT | -120.57% | -24.32% | 33.15% | 10.66% | 48.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 61.60% | -485.03% | -156.34% | 620.15% | 33.00% |
| Normalized Basic EPS | -634.62% | -272.47% | -581.82% | -138.40% | 82.67% |
| EPS Diluted | 61.60% | -485.03% | -156.34% | 620.15% | 33.00% |
| Normalized Diluted EPS | -634.62% | -272.47% | -581.82% | -138.40% | 82.67% |
| Average Basic Shares Outstanding | 33.09% | -11.01% | -13.61% | -17.91% | -19.14% |
| Average Diluted Shares Outstanding | 33.09% | -11.01% | -13.61% | -17.91% | -19.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |